Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL2-BCG phase II sequential bendamustine, obinutuzumab, and idelalisib trial in relapsed/refractory CLL
2014-000582-47Phase 2Completed
- Sponsor
- University of Cologne
- Start
- Feb 2015
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine, obinutuzumab and idelalisib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by University of Cologne. Primary endpoint: Overall response rate. Started Feb 2015; status: completed.
02
Drugs
bendamustineobinutuzumabidelalisib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2014-000582-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000582-47.